Other languages Arovella Therapeutics Limited

Equities

ALA

AU0000182784

Market Closed - Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
0.12 ^AUD	+4.35%		+14.29%	+4.35%

Mar. 26	Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	MT
Mar. 20	Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	Mar. 25
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	Mar. 19
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27
Arovella Boosts Solid Tumor Pipeline with Novel CAR-iNKT Cell Armouring Tech License	Jan. 30
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%	Jan. 01
Arovella Therapeutics Appoints CFO	Dec. 01
Arovella Therapeutics Limited Announces Changes to its Board	Nov. 30
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023	Nov. 20
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady	23-10-12
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%	23-10-11
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director	23-09-06
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30
Arovella Therapeutics Extends Closing Date of Share Purchase Plan	23-06-29
Arovella Therapeutics Ends AU$4.1 Million Placement; Launches AU$1 Million Purchase Plan	23-06-07
Arovella Therapeutics Completes Closure of Perth R&D Facility	23-05-01
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22
Arovella, Imugene's Collaboration on Tumor Cells Therapy Progresses to Next Phase	23-02-10
Arovella Therapeutics Limited and Imugene Announces Collaboration Advances to Next Phase of Testing	23-02-09
Arovella Therapeutics Ltd Appoints Dr. Nicole Van Der Weerden as Chief Operating Officer, January 4, 2023	23-01-03
Arovella Therapeutics Secures Exclusive Option to License Cytokine Technology for Cancer Therapy Platform	22-12-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Arovella Therapeutics Limited

Equities

ALA

AU0000182784

Other languages

Filters